ATE501253T1 - Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1 - Google Patents

Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1

Info

Publication number
ATE501253T1
ATE501253T1 AT04822466T AT04822466T ATE501253T1 AT E501253 T1 ATE501253 T1 AT E501253T1 AT 04822466 T AT04822466 T AT 04822466T AT 04822466 T AT04822466 T AT 04822466T AT E501253 T1 ATE501253 T1 AT E501253T1
Authority
AT
Austria
Prior art keywords
modulation
retinal pigmented
pigmented epithelial
epithelial permeation
inhibiting vegfr
Prior art date
Application number
AT04822466T
Other languages
English (en)
Inventor
Noriko Miyamoto
Nadia Normand
Jean Plouet
Francine Behar-Cohen
Original Assignee
Novagali Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali Pharma Sa, Inst Nat Sante Rech Med filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of ATE501253T1 publication Critical patent/ATE501253T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04822466T 2004-11-26 2004-11-26 Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1 ATE501253T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2004/004107 WO2006056823A1 (en) 2004-11-26 2004-11-26 Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1

Publications (1)

Publication Number Publication Date
ATE501253T1 true ATE501253T1 (de) 2011-03-15

Family

ID=34959531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04822466T ATE501253T1 (de) 2004-11-26 2004-11-26 Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1

Country Status (5)

Country Link
US (1) US20090087424A1 (de)
EP (1) EP1827602B1 (de)
AT (1) ATE501253T1 (de)
DE (1) DE602004031786D1 (de)
WO (1) WO2006056823A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US20070117750A1 (en) * 2005-10-06 2007-05-24 Muhammad Abdulrazik Method for enhanced ocular drug penetration
KR101083247B1 (ko) 2009-06-05 2011-11-14 중앙대학교 산학협력단 Ｆｔｙ720을 유효성분으로 포함하는 미백용 조성물
BR112016017817A2 (pt) * 2014-02-06 2017-10-10 Genzyme Corp composições e métodos para o tratamento e a prevenção de degeneração macular
EP3886946A1 (de) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Vorrichtungen und verfahren zur präzisionsdosisverabreichung
US12226452B2 (en) * 2020-03-04 2025-02-18 The Schepens Eye Research Institute, Inc. Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) * 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
ATE343400T1 (de) * 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
DE69736222T2 (de) * 1996-11-21 2007-05-24 Kyowa Hakko Kogyo K.K. Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
US6630973B1 (en) * 1999-03-31 2003-10-07 Fuji Photo Film Co., Ltd. Optically anisotropic cellulose ester film containing discotic compound
WO2001088574A1 (en) * 2000-05-15 2001-11-22 Fuji Photo Film Co., Ltd. Optical compensating sheet, polarizing plate, and liquid-crystal display
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
TW591298B (en) * 2001-07-23 2004-06-11 Nec Lcd Technologies Ltd Liquid crystal display device
DE60235761D1 (de) * 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US20040062751A1 (en) * 2002-01-17 2004-04-01 Genetix Pharmaceuticals, Inc. Methods for inhibiting angiogenesis
JP2003307621A (ja) * 2002-04-18 2003-10-31 Nitto Denko Corp 粘着型光学フィルムおよび画像表示装置
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
JP4054670B2 (ja) * 2002-12-13 2008-02-27 富士フイルム株式会社 偏光板および液晶表示装置
JP4301544B2 (ja) * 2003-01-07 2009-07-22 日東電工株式会社 画像表示装置の製造方法、画像表示装置および粘着型光学フィルム
WO2005000223A2 (en) * 2003-06-04 2005-01-06 Children's Medical Center Corporation Method of treating retinopathies and disorders associated with blood vessel loss

Also Published As

Publication number Publication date
WO2006056823A1 (en) 2006-06-01
WO2006056823A8 (en) 2006-08-24
EP1827602B1 (de) 2011-03-09
US20090087424A1 (en) 2009-04-02
EP1827602A1 (de) 2007-09-05
DE602004031786D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
CR8701A (es) Moduladores canabinoides de tetrahidro-indazol
BRPI0417697A (pt) inibidores de protease de aspartila heterocìclicos
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
EA201300272A1 (ru) Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
DK1608350T3 (da) Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation
WO2004101742A3 (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
WO2005072308A3 (en) Cgrp receptor antagonists
CA2620129C (en) Diaminopyrimidines as p2x3 and p2x2/3 modulators
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
ATE501253T1 (de) Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1
DE602004014823D1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
WO2010077976A3 (en) Prokineticin receptor antagonists and uses thereof
ATE451361T1 (de) Materialien und methoden zur behandlung von koagulationsstörungen
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
WO2005009340A3 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties